Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS (brentuximab vedotin), an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A, which is in Phase 1b trial for patients with newly diagnosed acute myeloid leukemia (AML); Phase 1/2 trial for patients with relapsed or refractory AML; Phase 1/2 trial for patients with previously untreated myelodysplastic syndrome; and Phase 1 trial for patients with AML. In addition, it is developing SGN-CD19A that is in Phase 2 trials for patients with relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase 1 trial for relapsed or refractory B-cell non-Hodgkin lymphomas, and relapsed or refractory B-cell acute lymphoblastic leukemia; SGN-LIV1A, which is in Phase 1 trial for the treatment of LIV-1-positive metastatic breast cancer; SGN-CD70A that is in Phase 1 trial for the treatment of CD70-positive renal cell carcinoma; SEA-CD40, which is in Phase 1 trial for the treatment of CD40-positive solid tumors; ASG-22ME that is in Phase 1 trial for the treatment of Nectin-4-positive solid tumors, including bladder cancer; and ASG-15ME, which is in Phase 1 trial for the treatment of bladder cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; PSMA Development Company LLC; Takeda Pharmaceutical Company Limited; and Unum Therapeutics, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Seattle Genetics Leukemia Drug Trials Halted, Stock Plunges The U.S. Food and Drug Administration has halted or partially halted several early stage clinical trials of a Seattle Genetics (SGEN) drug being developed to treat acute myeloid leukemia (AML), the company said Tuesday. Premarket trading in Seattle Genetics stocks was temporarily halted on the news, but when trading resumed shares were down 15%, near 52.50, which would mark a nearly two-month low. Seattle Genetics stock touched a record high of 75.36 on Nov. 10, and it had been up 38% for the year before Tuesday. investors.com
